We will be carefully reviewing the implications of this recommendation for use of these products, in the UK taking into account the availability of alternative treatments. We will seek advice from our Commission on Human Medicines next week and will communicate any new advice to clinicians following the meeting.
More ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment